CN114929265A - 个性化肿瘤疫苗及其用于癌症免疫疗法的用途 - Google Patents

个性化肿瘤疫苗及其用于癌症免疫疗法的用途 Download PDF

Info

Publication number
CN114929265A
CN114929265A CN202080086575.3A CN202080086575A CN114929265A CN 114929265 A CN114929265 A CN 114929265A CN 202080086575 A CN202080086575 A CN 202080086575A CN 114929265 A CN114929265 A CN 114929265A
Authority
CN
China
Prior art keywords
tumor
agent
dose
cell
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080086575.3A
Other languages
English (en)
Chinese (zh)
Inventor
Z·庄
R·麦迪纳
王合瑞
J·赞卡
K·潘凯克
W·霍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
South Bohemia University In Ceske Budejovice
Ne1 Co ltd
National Institutes of Health
Original Assignee
South Bohemia University In Ceske Budejovice
Ne1 Co ltd
National Institutes of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by South Bohemia University In Ceske Budejovice, Ne1 Co ltd, National Institutes of Health filed Critical South Bohemia University In Ceske Budejovice
Publication of CN114929265A publication Critical patent/CN114929265A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202080086575.3A 2019-12-11 2020-12-11 个性化肿瘤疫苗及其用于癌症免疫疗法的用途 Pending CN114929265A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962946934P 2019-12-11 2019-12-11
US62/946,934 2019-12-11
PCT/US2020/064412 WO2021119376A1 (en) 2019-12-11 2020-12-11 Personalized tumor vaccine and use thereof for cancer immunotherapy

Publications (1)

Publication Number Publication Date
CN114929265A true CN114929265A (zh) 2022-08-19

Family

ID=76330549

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080086575.3A Pending CN114929265A (zh) 2019-12-11 2020-12-11 个性化肿瘤疫苗及其用于癌症免疫疗法的用途

Country Status (7)

Country Link
US (1) US20230054318A1 (enExample)
EP (1) EP4072580A4 (enExample)
JP (1) JP2023508852A (enExample)
KR (1) KR20220141280A (enExample)
CN (1) CN114929265A (enExample)
AU (1) AU2020403013A1 (enExample)
WO (1) WO2021119376A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117903980A (zh) * 2024-01-05 2024-04-19 四川大学 一种海氏肠球菌及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115484985A (zh) * 2020-03-19 2022-12-16 崔泽尔有限公司 温度响应病毒储存系统
WO2022197599A1 (en) * 2021-03-18 2022-09-22 Ne1 Inc. Cancer vaccine and method of use thereof
CN115252782B (zh) * 2022-07-28 2023-05-19 重庆医科大学 一种携氧仿生分子探针及其制备方法和在hifu及免疫协同治疗癌症中的应用
EP4687901A1 (en) * 2023-03-29 2026-02-11 Biocanim A.s. A pharmaceutical combination for use in the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104840953A (zh) * 2007-10-09 2015-08-19 库瑞瓦格有限责任公司 治疗前列腺癌(PCa)的组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9370558B2 (en) * 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
GB0907989D0 (en) * 2009-05-08 2009-06-24 Hybrid Systems Ltd Multivalent adjuvant display
PH12013502442A1 (en) * 2011-05-26 2018-03-21 Glaxo Smithkline Biologicals Sa Inactivated dengue virus vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104840953A (zh) * 2007-10-09 2015-08-19 库瑞瓦格有限责任公司 治疗前列腺癌(PCa)的组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HERUI WANG等: "IMMU-23. TARGETING METASTATIC AND CNS TUMORS VIA MANNAN-BAM, TLR LIGANDS AND ANTI-CD40 ANTIBODY", NEURO ONCOLOGY, vol. 21, no. 6, 11 November 2019 (2019-11-11), pages 123 - 124 *
KRISTEN M. HEGE等: "GM-CSF Gene-Modifed Cancer Cell Immunotherapies: Of Mice and Men", INTERNATIONAL REVIEWS OF IMMUNOLOGY, vol. 25, 3 August 2009 (2009-08-03), pages 321 - 352, XP009128678 *
ROGELIO MEDINA等: "Induction of Immune Response against Metastatic Tumors via Vaccination of Mannan-BAM, TLR Ligands, and Anti-CD40 Antibody (MBTA)", ADVANCED THERAPEUTICS, vol. 3, no. 9, 9 June 2020 (2020-06-09), pages 1 - 15 *
RUI ZHANG等: "Biomaterials for vaccine-based cancer immunotherapy", JOURNAL OF CONTROLLED RELEASE, vol. 292, 9 October 2018 (2018-10-09), pages 256 - 276, XP055837284 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117903980A (zh) * 2024-01-05 2024-04-19 四川大学 一种海氏肠球菌及其应用

Also Published As

Publication number Publication date
WO2021119376A1 (en) 2021-06-17
EP4072580A1 (en) 2022-10-19
EP4072580A4 (en) 2023-12-20
KR20220141280A (ko) 2022-10-19
US20230054318A1 (en) 2023-02-23
AU2020403013A1 (en) 2022-06-02
JP2023508852A (ja) 2023-03-06

Similar Documents

Publication Publication Date Title
JP7765006B2 (ja) 新生児及び乳幼児におけるワクチン接種
US20230054318A1 (en) Personalized tumor vaccine and use thereof for cancer immunotherapy
US12274744B2 (en) Biomaterials for modulating immune responses
JP6525455B2 (ja) 免疫賦活活性を有するオリゴヌクレオチド含有複合体及びその用途
US12514865B2 (en) Biomaterial-based antigen free vaccine and the use thereof
CN105979961B (zh) 用于治疗癌症和感染性疾病的方法和组合物
Hou et al. Engineering a sustained release vaccine with a pathogen-mimicking manner for robust and durable immune responses
TW200902060A (en) Stimulation of an immune response by cationic lipids
JP2011026328A (ja) オリゴヌクレオチド組成物および免疫応答の調節のためのそれらの使用
JP2013535508A (ja) 抗体付きアジュバントを抗原提示細胞に直接的に標的化することをベースにした新規ワクチンアジュバント
US7981673B2 (en) Process for the maturation of dendritic cells and a vaccine
US11027017B2 (en) PCI method for generating immune respose to antigenic molecule using checkpoint inhibitor and TLR3 ligand
US20110165250A1 (en) Compositions and methods for treatment of neoplastic disease
US20240148855A1 (en) Cancer vaccine and method of use thereof
CN107567335A (zh) 支化的和线性的嵌合化合物、多核苷酸、它们的用途和制备方法
Jyoti et al. played by nanoimmunoadjuvants
Nukovic et al. Oxygen-generating cryogel vaccines help overcome tumor antigen tolerance and induce durable anti-tumor immunity in prostate cancer
WO2026073053A1 (en) Nanoparticle therapeutic vaccines that simultaneously co-deliver mhc class i and mhc class ii antigens and an adjuvant
Xu et al. Lipid-Glycoadjuvant@ AuNPs Inhibits Tumor Gowth and Regulates Tumor Microenvironments by Tumor-Specific CTL-Ferived IFNγ
WO2026034613A1 (ja) ｍＲＮＡワクチンアジュバント
CN116761625A (zh) 癌症免疫治疗
Koppolu Development and Evaluation of Chitosan Particle Based Antigen Delivery Systems for Enhanced Antigen Specific Immune Response
EA053080B1 (ru) Созданные иммуностимулирующие бактериальные штаммы и их применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220819

WD01 Invention patent application deemed withdrawn after publication